# Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients

> **NCT03311321** · NA · UNKNOWN · sponsor: **Augusta University** · enrollment: 60 (estimated)

## Conditions studied

- Cardiovascular Diseases
- Chronic Kidney Disease Stage 3
- Chronic Kidney Disease Stage 4
- Chronic Kidney Disease Stage 5
- Vitamin K Deficiency
- Hemodialysis

## Interventions

- **DIETARY_SUPPLEMENT:** Vitamin K2 (menaquinone-7; 360-mcg/d)
- **DIETARY_SUPPLEMENT:** Placebo-Control

## Key facts

- **NCT ID:** NCT03311321
- **Lead sponsor:** Augusta University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-13
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03311321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03311321, "Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03311321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*